Busy Amgen swings another deal, this time with RNA drugging player Arrakis for ‘several billion’

Less than a week after inking a $1.9 billion collaboration with Flagship’s Generate to boost its AI capabilities, Amgen is returning to the dealmaking table.

The biopharma’s newest partner is Arrakis, as the companies announced Tuesday morning they will team up to develop five RNA degrader therapeutics, with Amgen...

Click to view original post